{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:02:20Z","timestamp":1792796540524,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Because of limited information of Sertoli\u2013Leydig cell tumors (SLCTs), the objective aimed to describe clinical parameters, management and treatment results of SLCTs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>We retrospectively reviewed 15 cases with SLCTs, who were treated in the Affiliated Hospital of Qingdao University between 2009 and 2020. Data of clinical parameters and treatment was studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The age ranged 25\u201369\u2009years. Elevated testosterone was observed in 4 patients. FIGO-stage: 14 were at Ia(10 moderately differentiated, 3 poorly differentiated, 5 retiform pattern).1 was at Ic. Patients with retiform pattern were more likely to exhibit endocrine function (<jats:italic>p<\/jats:italic>\u2009=\u20090.019, w\u2009=\u20090.61) and tumor diameter was significantly bigger in no endocrine function (<jats:italic>p<\/jats:italic>\u2009=\u20090.012, d\u2009=\u20091.52). All patients received surgical treatment. 8 received postoperative chemotherapy. The median follow-up was 66\u2009months (20\u2013112\u2009months). 1 patient relapsed within 36\u2009months and received cytoreductive surgery. She survived without disease after recurrence treatment. Of 5 patients who performed fertility sparing surgeries with the desire of childbirth, 3 had full-term pregnancy and 1 experienced a miscarriage. Another one has not tried to conceive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The prognosis of SLCTs is good. Our data showed patients with retiform pattern were more likely to exhibit endocrine function. The diameter of tumor was significantly bigger in no endocrine function. Conservative surgery is the preferred option for patients with the desire of fertility at stage Ia. Postoperative chemotherapy is advised to cases with high-risk factors, but the most effective chemotherapy regimen is still uncertain.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-021-00909-7","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T16:02:42Z","timestamp":1636041762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Characteristics and outcomes analysis of ovarian Sertoli\u2013Leydig cell tumors (SLCTs): analysis of 15 patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Guangning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-5008","authenticated-orcid":false,"given":"Aiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"909_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s004040000114","volume":"264","author":"T Lantzsch","year":"2001","unstructured":"Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H. Sertoli-Leydig cell tumor. Arch Gynecol Obstet. 2001;264:206\u20138.","journal-title":"Arch Gynecol Obstet"},{"key":"909_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00000478-198508000-00001","volume":"9","author":"RH Young","year":"1985","unstructured":"Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol. 1985;9:543\u201369.","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 2","key":"909_CR3","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1038\/modpathol.3800311","volume":"18","author":"RH Young","year":"2005","unstructured":"Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol. 2005;18(Suppl 2):S81\u201398.","journal-title":"Mod Pathol"},{"key":"909_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ejca.2014.11.013","volume":"51","author":"DT Schneider","year":"2015","unstructured":"Schneider DT, Orbach D, Cecchetto G, Stachowicz-Stencel T, Brummel B, Brecht IB, et al. Ovarian Sertoli Leydig cell tumours in children and adolescents: an analysis of the European cooperative study group on pediatric rare tumors (EXPeRT). Eur J Cancer. 2015;51:543\u201350.","journal-title":"Eur J Cancer"},{"key":"909_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ygyno.2012.07.114","volume":"127","author":"T Gui","year":"2012","unstructured":"Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol. 2012;127:384\u20139.","journal-title":"Gynecol Oncol"},{"key":"909_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"909_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1447-0756.2012.01928.x","volume":"39","author":"RA Bhat","year":"2013","unstructured":"Bhat RA, Lim YK, Chia YN, Yam KL. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database. J Obstet Gynaecol Res. 2013;39:305\u201310.","journal-title":"J Obstet Gynaecol Res"},{"key":"909_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/uog.5227","volume":"31","author":"VN Demidov","year":"2008","unstructured":"Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol. 2008;31:85\u201391.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"909_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.tjog.2012.03.001","volume":"52","author":"CS Weng","year":"2013","unstructured":"Weng CS, Chen MY, Wang TY, Tsai HW, Hung YC, Yu KJ, et al. Sertoli-Leydig cell tumors of the ovary: a Taiwanese gynecologic oncology group study. Taiwan J Obstet Gynecol. 2013;52:66\u201370.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"909_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/09513590.2012.738723","volume":"29","author":"H Xiao","year":"2013","unstructured":"Xiao H, Li B, Zuo J, Feng X, Li X, Zhang R, et al. Ovarian Sertoli-Leydig cell tumor: a report of seven cases and a review of the literature. Gynecol Endocrinol. 2013;29:192\u20135.","journal-title":"Gynecol Endocrinol"},{"key":"909_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/01443615.2017.1291590","volume":"37","author":"LM Melero Cort\u00e9s","year":"2017","unstructured":"Melero Cort\u00e9s LM, Mart\u00ednez Maestre M, Vieites P\u00e9rez-Quintela MB, Gambadauro P. Ovarian Sertoli-Leydig cell tumours: how typical is their typical presentation? J Obstet Gynaecol. 2017;37:655\u20139.","journal-title":"J Obstet Gynaecol"},{"key":"909_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/0973-1482.158037","volume":"12","author":"L Akman","year":"2016","unstructured":"Akman L, Ertas IE, Gokcu M, Terek MC, Sanci M, Sanli UA, et al. Ovarian sertoli-leydig cell tumors: a multicenter long-term clinicopathological analysis of 27 patients. J Cancer Res Ther. 2016;12:290\u20134.","journal-title":"J Cancer Res Ther"},{"key":"909_CR13","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1634\/theoncologist.2017-0632","volume":"24","author":"S Gouy","year":"2019","unstructured":"Gouy S, Arfi A, Maulard A, Pautier P, Bentivegna E, Leary A, et al. Results from a monocentric long-term analysis of 23 patients with ovarian Sertoli-Leydig cell tumors. Oncologist. 2019;24:702\u20139.","journal-title":"Oncologist"},{"issue":"Suppl 7","key":"909_CR14","doi-asserted-by":"publisher","first-page":"vii20","DOI":"10.1093\/annonc\/mds223","volume":"23","author":"N Colombo","year":"2012","unstructured":"Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii20\u20136.","journal-title":"Ann Oncol"},{"key":"909_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00404-020-05588-1","volume":"302","author":"Y Guo","year":"2020","unstructured":"Guo Y, Wang J, Li Y, Wang Y. Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases. Arch Gynecol Obstet. 2020;302:203\u20138.","journal-title":"Arch Gynecol Obstet"},{"key":"909_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ygyno.2012.03.024","volume":"125","author":"C Sigismondi","year":"2012","unstructured":"Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, et al. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. Gynecol Oncol. 2012;125:673\u20136.","journal-title":"Gynecol Oncol"},{"key":"909_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1447-0756.2008.00866.x","volume":"35","author":"V Kawatra","year":"2009","unstructured":"Kawatra V, Mandal S, Khurana N, Aggarwal SK. Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl. J Obstet Gynaecol Res. 2009;35:176\u20139.","journal-title":"J Obstet Gynaecol Res"},{"key":"909_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2559.2002.01426.x","volume":"41","author":"EE Mooney","year":"2002","unstructured":"Mooney EE, Nogales FF, Bergeron C, Tavassoli FA. Retiform Sertoli-Leydig cell tumours: clinical, morphological and immunohistochemical findings. Histopathology. 2002;41:110\u20137.","journal-title":"Histopathology"},{"key":"909_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5468\/ogs.2017.60.1.39","volume":"60","author":"SM Nam","year":"2017","unstructured":"Nam SM, Kim JW, Eoh KJ, Kim HM, Lee JY, Nam EJ, et al. A novel clinicopathological analysis of early stage ovarian Sertoli-Leydig cell tumors at a single institution. Obstet Gynecol Sci. 2017;60:39\u201345.","journal-title":"Obstet Gynecol Sci"},{"key":"909_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ygyno.2005.01.011","volume":"97","author":"J Brown","year":"2005","unstructured":"Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97:489\u201396.","journal-title":"Gynecol Oncol"},{"key":"909_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cncr.28421","volume":"120","author":"J Brown","year":"2014","unstructured":"Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the gynecologic oncology group. Cancer. 2014;120:344\u201351.","journal-title":"Cancer"},{"key":"909_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/PAS.0000000000000895","volume":"41","author":"L de Kock","year":"2017","unstructured":"de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, Foulkes WD, et al. DICER1 mutations are consistently present in moderately and poorly differentiated Sertoli-Leydig cell tumors. Am J Surg Pathol. 2017;41:1178\u201387.","journal-title":"Am J Surg Pathol"},{"key":"909_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/PAS.0000000000001232","volume":"43","author":"AN Karnezis","year":"2019","unstructured":"Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, et al. DICER1 and FOXL2 mutation status correlates with Clinicopathologic features in ovarian Sertoli-Leydig cell tumors. Am J Surg Pathol. 2019;43:628\u201338.","journal-title":"Am J Surg Pathol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00909-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T16:03:15Z","timestamp":1636041795000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00909-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00909-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Affiliated Hospital of Qingdao University, and written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}